Congenital Heart Disease
ACHD management and long-term outcomes
Emerging evidence with 91 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does rivaroxaban vs placebo improve outcomes in Congenital Heart Defects?
Low Certainty+ Favors benefitrivaroxaban vs placebo · Cardiac Output
Does levosimendan vs placebo improve Cardiac Output in Low Cardiac Output Syndrome?
Low Certainty− Favors harmlevosimendan vs placebo · Cardiac Output
Congenital heart disease adults (also known as ACHD, adult congenital, grown-up congenital heart). ACHD management and long-term outcomes
Synapse tracks 2 specific clinical questions in Congenital heart disease adults, each synthesized independently from its own trial evidence. They include: "Does rivaroxaban vs placebo improve outcomes in Congenital Heart Defects?"; "Does levosimendan vs placebo improve Cardiac Output in Low Cardiac Output Syndrome?".
As of 2026-06-25, the scientific consensus on Congenital heart disease adults is emerging. Emerging evidence with 91 primary claims Based on 91 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/69b0a321b42209bc31dca35d.
Deterministic synthesis from Synapse's enriched corpus — 103 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Congenital heart disease adults paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Congenital heart disease adults papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers